Introduction

D
eregulated activation of the Jak/Stat pathway has been implicated in the pathogenesis of many cancers. The growth of these malignancies is often associated with promiscuous phosphorylation of Stat3 and Stat5. Aberrant phosphorylation of these transcription factors may be mediated by constitutive activation of the tyrosine kinases Jak1 or Jak2. Jak1 activation has been associated with transformation by Src or v-Abl others 1995, 1998; Zhang and others 2000) , whereas the TEL-JAK2 fusion oncogene and gain-of-function mutations in Jak2 have been implicated in the pathogenesis of leukemias and myeloproliferative disorders (Kralovics and others 2005) .
Tyk2 is a member of the Jak family, which primarily mediates the actions of type 1 interferons (IFNa/b) and interleukin (IL)-12. It has also been implicated in signaling by several other cytokines, including IL-10, IL-6, and IL-13.
Tyk2
-/ -mice display a variety of defects in both innate and adaptive immunity consistent with their roles in mediating the actions of IFNa/b and IL-12. In contrast to Jak1 and Jak2, which have been clearly implicated in cell transformation, the role of Tyk2 in cancer is ambiguous and very limited. In DU-145 human prostate cancer cells disruption of the expression of Tyk2 with siRNA inhibited the ability of these cells to migrate in a matrigel invasion assay (Ide and others 2008) . In contrast to the expression of Tyk2 facilitating the ability of prostate cancer cells to invade, Tyk2 -/ -mice are more susceptible to Abelson murine leukemia virus-induced B cell leukemia/lymphoma and TEL-JAK2-induced T cell lymphoid leukemia (Lacronique and others 1997; Carron and others 2000; Stoiber and others 2004) . The lack of Tyk2 expression in this tumor model is associated with decreased cytotoxicity of Tyk2 -/ -NK and NKT cells (Stoiber and others 2004) .
Considering that both IFNa/b and IL-12 have antitumor activity, and mediate activation of the Jak/Stat pathway through Tyk2, we initiated a series of experiments in Tyk2 -/ -mice to examine whether the expression of Tyk2 influences the ability of 4T1 breast cancer cells to grow and metastasize. We chose 4T1 cells for these studies because they were derived from a spontaneous mouse mammary carcinoma and closely resemble the pathology of human breast cancer. 4T1 tumors metastasize to the lung, liver, brain, and bone relatively early during the growth of the primary tumor. This model for breast cancer also has the advantage that the tumors grow and metastasize in immunocompetent BALB/C mice.
Materials and Methods
Cells
The 4T1 mouse mammary carcinoma cell line was purchased from the American Type Culture Collection. Cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS; Serum Source International, Inc.), 1.0 mM sodium pyruvate, 100 U/mL penicillin, and 100 mg/mL streptomycin (Mediatech, Inc.).
Mice
BALB/cJ mice were purchased from Jackson Laboratory.
Tyk2
-/ -mice (Shimoda and others 2000) on a BALB/c background were obtained from Dr. Ana M. Gamero (Temple University). Tyk2
-/ -mice were genotyped by using the following primers. Forward primer for Tyk2 + / + mice: 5¢-TGG ACA AAA TGG AGT GAG TGT AAG-3¢; reverse primer for Tyk2 + / + mice: 5¢-CTG GGT CAT GGC TGG AAA AGC CCA-3¢; primers for Tyk2 -/ -mice: 5¢-GAT CGG CCA TTG AAC AAG ATG-3¢; 5¢-CGC CAA GTC CTT CAG CAA TAT-3¢. Only female mice were used for these studies. 
Reagents and antibodies
In vivo tumor study
Female mice were used for these studies. Mice were subcutaneously injected in the mammary gland with 7.0 · 10 3 4T1 cells in 1· PBS. Tumor growth was assessed morphometrically using calipers, and tumor volumes were calculated according to the formula V (mm 3 ) = L (length) · W 2 (width)/2 (4). Tumors and spleens from control and tumorbearing mice were weighed on a microbalance. This research was conducted under a protocol approved by Virginia Commonwealth University, Institutional Animal Care and Use Committee.
Metastatic tumor cell clonogenic assay
4T1 tumor cells are 6-thioguanine resistant. Metastatic cells were quantified by removing organs, plating dissociated cells in medium supplemented with 6-thioguanine, and counting the number of 6-thioguanine-resistant colonies. Lungs and livers were harvested from each experimental group. Liver samples were finely minced and digested in 5 mL of enzyme cocktail containing 1· PBS, 0.01% BSA, 1 mg/mL hyaluronidase, and 1 mg/mL type I collagenase for 20 min at 37°C. Lung samples were minced and digested in enzyme cocktail containing 1· PBS, 1 mg/mL collagenase type IV at 6 units/ mL for 75 min at 4°C. After incubation, samples were filtered through 70-mm nylon cell-strainers and washed 2 or 3 times with 1· PBS. Cells were plated with a series of dilutions on 10-cm tissue-culture dishes in DMEM containing 60 mM 6-thioguanine. At this concentration of 6-thioguanine there were no viable cells from liver or lung isolated from mice not innoculated with 4T1 cells (data not shown). Tumor cells formed foci after 10 to14 days, at which time they were fixed with methanol and stained with 0.03% methylene blue. Clonogenic metastases were calculated on a per-organ basis.
IFNg production
Tyk2
+ / + and Tyk2 -/ -female mice were inoculated with 4T1 cells in the mammary gland. After 5 days of tumor growth, spleens were harvested. Splenocytes (5 · 10 6 ) were then cocultured in the presence of IL-2 (30 U/well) in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin in the presence or absence of irradiated 4T1 cells (4 · 10 5 ) (15,000 rads). After 24 h of incubation, the supernatants were collected. IFNg concentration in these supernatants was determined using a mouse IFNg ELISA set (BD Biosciences) according to manufacture's protocol. IFNg and other cytokines were also assayed in supernatants from primary 4T1 cell tumors grown in Tyk2 + / + or Tyk2
-/ -mice. Tumors were collected 34 days after inoculation, and equal weights of tumor were minced and incubated in RPMI 1640 with penicillin/streptomycin for 24 h. Supernatants were analyzed using the mouse inflammation cytometric bead assay kit (BD Biosciences) according to the manufacture's instructions.
In vivo depletion of lymphoid cells
In vivo NK cell depletion was performed using purified monoclonal antibodies to anti-asialo-GM1 (Cat # 986-1001Wako Chemicals, Richmond, VA). Recipient mice were injected intraperitoneally (i.p.) with 200 mg of rabbit antiasialo GM1 or control rabbit Ig serum (SLR66; Equitech-Bio, Inc.) before tumor inoculation. Antibody injections were performed on days 0, 1, 7, 11, 14, and 20, where day 1 is the day of tumor challenge. NK-cell depletion was confirmed by flow cytometric analysis of peripheral blood lymphocytes. The presence of NK cells was examined on the following day after each antibody injection by flow analysis staining with anti-mouse FITC-Pan-NK (DX5) (Biolegend) and anti-mouse PE-CD3e (Biolegend) on a FACS Canto TM II flow cytometer. In vivo T-cell depletion was performed using purified monoclonal antibodies of anti-CD4 (GK1.5) or anti-CD8 (2.43). Mice were depleted of CD4 + or CD8 + T cells by i.p. injection of 200 mg Ab. Antibodies were injected on days 1, 6, and 13. Mice were inoculated with 4T1 cells on day 2. The presence of CD4 + or CD8 + T cells was examined on the day following injection by flow cytometric analysis using anti-CD4-FITC (Clone RM4-5), anti-CD3e-PE (Clone 145-2C11), and anti-CD8-FITC (Clone 53-6.7). Control mice were inoculated with 200 mg of purified normal mouse IgG (SLM66; Equitech-Bio, Inc.).
Myeloid-derived suppressor cell numbers in tumor-bearing mice
Viable cells were counted and splenocytes (1 · 10 6 ) were stained for 30 min with anti-mouse CD11b (PE-conjugated) and anti-mouse Gr-1 (PE/Cy5-conjugated) (Biolegend). Myeloid-derived suppressor cells (MDSCs) in spleens were analyzed in a BD FACS Canto TM II flow cytometer.
Carboxyfluorescein diacetate, succinimidyl ester labeling
Splenocytes were resuspended in 5 mM of carboxyfluorescein diacetate, succinimidyl ester (CFSE; Invitrogen Cat. No. C34554) in HBSS medium and incubated at room temperature for 5 min, after which 1 mL of heat inactivated FBS was added. Cells were centrifuged at 1,400 rpm for 5 min at 4°C and washed 3 times with HBSS containing 10% heatinactivated FBS.
In vitro MDSC suppression of T cell proliferation
Ninety-six-well plates were coated with 200 ml of 10 mg/ mL anti-CD3e (BD Pharmingen) and incubated for 24 h at 4°C. Unbound antibody was removed by washing 3 times with PBS. Splenocytes (10 7 cells/mL in complete media) isolated from naïve Tyk2
+ / + and Tyk2 -/ -mice were used as responder cells. Splenocytes from tumor-bearing Tyk2 + / + and tumor-bearing Tyk2
-/ -mice were stained with antiCD11b and anti-Gr1 serum and sorted to collect CD11b 
Gr1
+ cells (MDSCs). Sorted MDSCs were incubated with CFSE-labeled naïve splenocytes in 1:2 ratio added directly to the culture medium in the presence of IL-2. Soluble anti-CD28 antibody (BD Pharmingen) was also added to the culture medium at 1 mg/mL. Splenocytes were plated at 2 · 10 5 cells/well and were allowed to proliferate for 48 h at 37°C in 5% CO 2 . Cells were collected and Fc receptors were blocked with anti-CD16/32. Splenocytes were stained with anti-CD3e and anti-CD4 or anti-CD3e and anti-CD8. CD4 + or CD8 + T cell proliferation was monitored by flow cytometry for decreases in CFSE fluorescence.
Statistical analysis
Statistical analysis was performed using analysis of variance (ANOVA) for tumor volume and metastatic disease.
Other differences between 2 groups were analyzed with the Student's t-test. Results of tumor growth in mice are presented as the means -standard errors (SE) of tumor volume in each group. P < 0.05 was considered statistically significant.
Results
Initial experiments were performed to determine whether Tyk2 played a role in the modulation of tumor growth and metastasis of 4T1 cells. Female mice were inoculated subcutaneously in the mammary gland with 4T1 cells. Tumor volume at the site of injection was measured using calipers every 7 days (Fig. 1A ). Mice were sacrificed on day 29 postinoculation and weights of the primary tumor were measured (Fig. 1B) . Compared with Tyk2 + / + mice tumor volumes were about 2-fold greater and tumor weights were 3.5-fold greater when tumors were grown in Tyk2
-/ -animals. Spleen weights from Tyk2
-/ -mice were also increased about 4-fold compared to Tyk2 + / + mice (Fig. 1C ). 4T1 tumors have the capacity to spontaneously metastasize to a variety of organs, including liver and lung (OstrandRosenberg 2004) . Since 4T1 cells are 6-thioguanine resistant, we used clonogenic assays to measured metastatic foci in the liver and lungs of Tyk2 + / + and Tyk2 -/ -mice ( Fig. 2A, B ). The numbers of metastatic colonies in both tissues were significantly elevated in Tyk2 -/ -compared with Tyk2 + / + tissues. There are 2 possible interpretations of this result. (1) Since primary tumors are larger in Tyk2
-/ -animals, they may metastasize earlier than tumors in Tyk2 + / + mice, thereby providing a longer time for more metastatic colonies to form. (2) There is an intrinsic deficiency in Tyk2
-/ -mice that allows the tumors to metastasize with greater efficiency. To distinguish between these possibilities, mice were given intravenous tail vein injections of 4T1 cells, and 10 days later the number of metastatic colonies in the lungs and liver were determined by clonogenic assays (Fig. 3A, B) . The numbers of metastatic colonies were significantly greater in both the lungs and livers of Tyk2 -/ -animals, suggesting that the enhanced size of the primary tumors is not the only mechanism accounting for more metastasis in Tyk2 -/ -organs. 
TYK2 AND BREAST CANCER
The design of this experiment does not address the possibility that in a Tyk2-null background the ability of cancer cells to invade is also enhanced.
Key components of tumor surveillance are NK cells, CD4
+ , CD8 + T cells, and the production of IFNg. Opposing the actions of these players are MDSCs, which promote tumor growth by inhibiting T cell function (Gabrilovich and Nagaraj 2009 ). We investigated whether defects in these populations contributed to the enhanced growth of 4T1 cells in Tyk2
-/ -mice. IFNg production was measured in supernatants collected from irradiated 4T1 cells cocultured with splenocytes from Tyk2 + / + or Tyk2 -/ -tumor-bearing mice (Fig. 4A) . IFNg production was decreased about 5-fold in Tyk2
-/ -splenocytes from tumor-bearing mice (Fig. 5A ). These results are consistent with defects in IL-12 induction of IFNg that has been identified in Tyk2 -/ -mice (Karaghiosoff and others 2000; Shimoda and others 2000).
We also analyzed the production of IFNg and other cytokines in supernatants of primary 4T1 cell tumors isolated from Tyk2 + / + and Tyk2 -/ -mice. The amount of IFNg produced from tumors derived from Tyk2 + / + mice was about 2.5-fold greater than that produced from tumors derived from Tyk2 -/ -animals (Fig. 4B ). The production of inflammatory cytokines, including TNFa, MCP1, and IL-6, was not statistically different in the samples (data not shown).
To determine whether defects in NK cells account for enhanced tumor growth in Tyk2 -/ -mice, mice were pretreated with antibodies to NK cells 1 day before inoculation with 4T1 cells (day 2). Mice were given additional antibody injections on days 7, 14, and 21 (Fig. 5A ). Before depletion, lymphocytes from Tyk2 + / + blood contained about 7% NK cells, whereas Tyk2
-/ -lymphocytes contained 5% NK cells (Fig. 5B) . This difference in NK cell numbers was not statistically significant. Compared with animals injected with IgG control, NK antibody-treated mice contained about 0.1% NK cells (Fig. 5B) . Depletion of NK cells caused a modest increase in the rate of tumor growth in both Tyk2 + / + and Tyk2 -/ -mice (Fig. 5C ). These results suggest that Tyk2-mediated changes in NK cell activity do not contribute to the accelerated rate of tumor growth observed in Tyk2 -/ -mice.
Mice were also injected with either anti-CD4 or anti-CD8 antibodies to examine whether the loss of activity of these lymphocyte populations contributed to enhanced rates of 4T1 cell growth in Tyk2 -/ -mice. Blood from Tyk2 + / + and Tyk2 -/ -mice contained approximately the same percentage of CD4 + and CD8 + T cells (data not shown). Treatment of mice with either antibody depleted CD4 or CD8 cells to 0.1% of the total population (data not shown). Depletion of CD4 + cells had no effect on the rates of tumor growth in either Tyk2 + / + or Tyk2 -/ -mice. Mice depleted of CD8 + cells showed a slightly increased rate of tumor growth. However, the differences in rates of tumor growth between Tyk2 + / + and Tyk2 -/ -mice were maintained in the absence of CD8 cells (Fig. 6A, B) .
MDSCs are a heterogenous population of cells comprised of myeloid progenitor cells, immature macrophages,
FIG. 2. Tyk2
-/ -mice inoculated with 4T1 cells display increased metastatic disease. Tyk2 + / + and Tyk2 -/ -mice (n = 12) were injected with 4T1 cells in the abdominal mammary gland. Twentynine days after inoculation, mice were sacrificed and livers and lungs were collected. Cells isolated from these tissues were plated on 6-thioguanine and colonies were counted after 12-14 days. -/ -mice were used for these experiments.
674
ZHANG ET AL.
immature granulocytes, and immature dendritic cells, all of which suppress T cell function (Gabrilovich and Nagaraj 2009) . Numbers of MDSCs increase in spleens of tumorbearing animals. To determine the possible role of MDSCs in 4T1 cell growth, MDSC levels were measured in the spleens of Tyk2 + / + and Tyk2 -/ -mice 21 days after inoculation (Fig.  7 ). There were approximately 2.5 times as many splenic MDSCs in Tyk2
-/ -compared to Tyk2 + / + animals. To determine whether there were changes in the ability of MDSCs from Tyk2 -/ -tumor-bearing mice to suppress T cell proliferation, splenic MDSCs were sorted from Tyk2 + / + and Tyk2 -/ -mice. MDSCs were cocultured with Tyk2 -/ -or Tyk2 + / + naïve splenocytes labeled with CFSE. Proliferation of CD4
+ and CD8 + cells was analyzed by flow cytometry (Fig. 7A, B) . Compared with MDSCs from Tyk2 + / + spleens, Tyk2 -/ -spleens have a slight, but significant, increase in suppression of both CD4
+ and CD8 + T cell proliferation. The increased suppressive effects of MDSCs from Tyk2
-/ -mice were not dependent on whether the T cells used in the assay originated from Tyk2 -/ -or Tyk2 + / + animals.
Discussion
Although there are many reports indicating that promiscuous activation of Stat3, Stat5, and Jak1 and Jak2 is associated with cell transformation, our understanding of the role + / + and Tyk2 -/ -mice depleted of NK cells, tumors in Tyk2 -/ -mice remained increased compared to Tyk2 + / + mice in the absence of NK cells.
FIG. 4. Tyk2
-/ -splenocytes sensitized to 4T1 cells produce less interferon-g (IFNg) than Tyk2 + / + splenocytes. Mice (n = 8) were inoculated with 4T1 cells. After 5 days, spleens were harvested. (A) Splenocytes (5 · 10 6 ) were cocultured with IL-2 in the presence or absence of irradiated 4T1 (4 · 10 5 cells) (15,000 rads). After 24 h, the supernatants were collected and IFNg concentration was determined using an IFNg ELISA kit. Data bars represent means and standard errors p < 0.03. (B) IFNg production in tumors isolated from mice inoculated with 4T1 cells was measured as described. Tumors were harvested 7 days after introduction of 4T1 cells into Tyk2
TYK2 AND BREAST CANCER ) labeled with carboxyfluorescein diacetate, succinimidyl ester. After 48 h incubation, cells were stained with anti-CD3-PE and anti-CD4-PE/Cy5 or anti-CD8a-PE.Cy5. (B) MDSCs are more effective than Tyk2 + / + MDSCs in suppressing T cell proliferation. CD4 + T cell proliferation was measured in cells isolated from Tyk2 + / + or Tyk2
-/ -mice (C) CD8 + T cell proliferation was measured under the same conditions as CD4 + cells.
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potential of tumors in a Tyk2 -/ -background is not simply due to the increased size of the primary tumors. To determine which hematopoietic cells may be altered by the expression of Tyk2, wild-type and Tyk2
-/ -mice were depleted of NK, CD4 + , or CD8 + T cells. Our results indicate that the antigrowth function of these cells is not altered by the expression of Tyk2. These findings contrast with those of Stoiber and others, who demonstrated that the expression of NK and NKT cells plays a major role in suppressing the development of A-MuLV-induced lymphomas in Tyk2 -/ -mice (Stoiber and others 2004) .
Although NK cells, CD4 + , and CD8 + T cells do not influence the ability of 4T1 cells to form tumors in a Tyk2-dependent manner, it appears that the ability of MDSCs to inhibit the growth of T cells is enhanced in the absence of Tyk2. It remains unclear whether the expression of Tyk2 in MDSCs is solely responsible for altering the rate of 4T1 cell tumor growth and metastasis, or the expression of Tyk2 in other cells plays a role in inhibiting tumor progression. It is possible that decreased IFNg production observed in tumors and the splenocytes of Tyk2
-/ -mice also contributes to the inhibitory effects of Tyk2. IFNg mediates its antitumor effects through activation of Stat1, and Stat1 does play an important role in immune surveillance (Koebel and others 2007) . It is interesting to note that levels of Stat1 are decreased in a variety of tissues in Tyk2 -/ -mice and the ability of IFNg to stimulate tyrosine phosphorylation of Stat1 is also diminished (Karaghiosoff and others 2000; Shimoda and others 2000) . Since Stat1 and IFNg play important roles in tumorimmune-system interactions, it is likely that Tyk2 expression also affects the ability of the immune system to respond to tumor challenge others 2005, 2006) .
There is no evidence that mutations in Tyk2 might predispose to tumor formation. However, one can envisage such a scenario. In addition to mutations that abolish the kinase activity of Tyk2, mutations may occur in the protein that partially affect the ability of IL-12 to induce T cell production of IFNg, which plays a pivotal role in promoting antitumor responses. In addition to mutations that modify kinase activity of Tyk2, other mutations in the protein that prevent it from associating with type 1 IFN or IL-12 receptors (FERM domain mutations) could account for naturally occurring defects in Tyk2 function. Screens to identify such defects in patients with a variety of malignancies, including breast cancer, might be informative in terms of both prognosis and appropriate treatment.
